Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole in LPR and Comorbid CRS
NCT03086070Phase 4Completed
- Sponsor
- Children's Hospital Srebrnjak
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in laryngopharyngeal reflux (LPR) and chronic rhinosinusitis (CRS) comparing Omeprazole 20mg with Placebo (2 arms). Primary endpoints: Reduction in signs and symptoms of laryngopharyngeal reflux at 8 weeks and Reduction in signs of laryngopharyngeal reflux at 8 weeks. Started Jan 2010; status: completed.
02
Drugs
omeprazole
03
Conditions
laryngopharyngeal reflux (LPR)chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03086070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086070.